One year after the launch of nirsevimab (Beyfortus), the first RSV immunization for infants, hospitalizations for respiratory syncytial virus in babies under 6 months have plummeted 78%.
The Impact
- RSV hospitalizations in infants down 78%
- ICU admissions down 82%
- Estimated 3,400 infant deaths prevented in the first year
- $1.2 billion saved in healthcare costs
How It Works
Nirsevimab is a monoclonal antibody given as a single injection, providing 5 months of protection during RSV season. It's not technically a vaccine but an antibody that provides immediate protection — no immune response needed.
Who Should Get It
All infants under 8 months entering their first RSV season, and high-risk children 8-19 months. The injection is recommended by the CDC and covered by all insurance plans with zero copay under the Vaccines for Children program.
RSV was previously the leading cause of infant hospitalization in the U.S. This single intervention has transformed pediatric winter care and is being called one of the most impactful public health advances in a decade.
